LifeMD, Inc. LFMD
is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients
to access virtual medical care and pharmacy services. We believe the traditional healthcare model requiring patients to visit a physician's
office, travel to a retail pharmacy, and return for follow-up appointments or prescription refills is complex, inefficient, and costly
which can discourage individuals from seeking necessary medical care and medications. At the same time, the United States ("U.S.")
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Telehealth Subscription Revenue
- Telehealth
| Segment | FY2025 |
|---|---|
| Telehealth Subscription Revenue | $113.3M |
| Telehealth | $80.8M |
As the company reported it, from the “SCHEDULE OF DISAGGREGATED REVENUE (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $194.1M | $154.8M | $152.5M | $119.0M | $92.9M | $37.3M | $12.5M | $42.5K | $23.2K | $5.2M |
| Cost of revenue | $27.7M | $21.4M | $18.9M | $18.7M | $18.0M | $8.9M | $2.5M | $2.0M | $1.0M | $1.9M |
| Gross profit | $166.3M | $133.4M | $133.6M | $100.4M | $74.9M | $28.4M | $9.9M | $6.3M | $2.7M | $3.3M |
| SG&A | $57.9M | $57.9M | $51.7M | $47.0M | $39.5M | $45.0M | $2.4M | $2.3M | $742.0K | $1.0M |
| Total operating expenses | $174.0M | $153.8M | $148.1M | $143.8M | $129.2M | $86.3M | $12.8M | $8.4M | $3.9M | $4.5M |
| Operating income | -$7.7M | -$20.4M | -$14.5M | -$43.4M | -$54.3M | -$57.8M | -$2.9M | -$2.1M | -$1.2M | -$1.2M |
| Interest expense | $1.4M | $2.2M | $2.6M | $1.3M | $3.0M | $1.7M | $761.1K | $354.4K | $100.5K | $48.6K |
| Pre-tax income | -$10.2M | -$22.6M | -$17.4M | -$44.7M | -$61.3M | -$60.4M | -$3.7M | -$2.4M | -$1.4M | -$1.2M |
| Income tax | $45.7K | $598.0K | $428.0K | $360.7K | $7.7K | $122.5K | $122.5K | $124.7K | — | — |
| Net income | -$11.2M | $24.5M | $17.8M | -$45.5M | -$60.9M | -$58.6M | -$3.1M | -$1.2M | -$1.2M | -$1.1M |
| EPS, basic | 0.25 | -0.60 | — | — | — | — | — | — | -0.03 | -0.03 |
| EPS, diluted | 0.25 | -0.60 | — | — | — | — | — | — | -0.03 | -0.03 |
| Shares, diluted (wtd. avg.) | 45.1M | 41.2M | 33.9M | 31.0M | 27.0M | 14.3M | 9.9M | 44.2M | 41.7M | 33.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $36.8M | $32.7M | $33.1M | $4.0M | $41.3M | $9.2M | $1.1M | $180.1K | $141.4K | $182.6K |
| Receivables | $9.3M | $10.5M | $5.3M | $2.8M | $980.1K | $997.8K | $97.4K | $99.1K | $128.2K | $444.7K |
| Inventory | $2.8M | $2.8M | $2.8M | $3.7M | $1.6M | $1.3M | $950.1K | $1.0M | $681.3K | $160.3K |
| Total current assets | $51.8M | $52.4M | $42.6M | $11.3M | $44.9M | $12.4M | $2.7M | $1.6M | $1.3M | $789.8K |
| Property, plant and equipment | $2.4M | $1.4M | $476.3K | $476.4K | $233.8K | — | — | — | — | — |
| Goodwill | — | — | — | $8.0M | $0 | — | — | — | — | — |
| Other intangibles | $262.3K | $53.3K | $3.0M | $3.8M | $19.8K | $339.8K | $675.5K | $1.0M | — | — |
| Total assets | $70.4M | $76.1M | $58.5M | $25.7M | $49.9M | $13.4M | $3.4M | $2.6M | $1.3M | $789.8K |
| Accounts payable | $14.1M | $10.9M | $11.1M | $10.1M | $9.1M | $10.4M | $3.1M | $869.0K | $422.3K | $752.9K |
| Total current liabilities | $41.6M | $67.4M | $34.8M | $31.4M | $22.8M | $13.9M | $4.0M | $1.2M | $641.0K | $1.2M |
| Total liabilities | $47.3M | $83.7M | $52.9M | $33.0M | $24.1M | $14.2M | $4.6M | $1.8M | $641.0K | — |
| Retained earnings | -$228.6M | -$239.9M | -$214.3M | -$190.6M | -$141.9M | -$80.2M | -$16.6M | -$12.1M | -$10.9M | -$9.7M |
| Total equity | $23.2M | -$9.1M | $4.2M | -$11.9M | $21.7M | -$4.5M | -$1.1M | $819.7K | $622.8K | -$361.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.3M | $17.5M | $8.8M | -$22.9M | -$33.1M | -$12.1M | $251.4K | -$905.5K | -$817.2K | -$407.9K |
| Depreciation and amortisation | $865.5K | $465.8K | $204.0K | $161.9K | $13.6K | — | — | — | — | — |
| Stock-based compensation | $10.5M | $12.2M | $12.5M | $13.7M | $12.1M | $18.7M | $733.2K | $273.6K | $162.7K | $588.0K |
| Capital expenditure | $1.9M | $1.5M | $203.8K | $366.6K | $247.4K | — | — | — | — | — |
| Investing cash flow | $6.9M | -$11.5M | -$8.7M | -$13.9M | -$3.4M | -$798.1K | -$100.0K | $141.4K | — | — |
| Financing cash flow | -$13.4M | -$4.1M | $29.1M | -$528.2K | $68.6M | $21.0M | $775.1K | $802.8K | $776.0K | $357.5K |
| Dividends paid | $3.1M | $3.1M | $3.1M | $3.1M | $871.5K | — | — | — | — | — |
| Buybacks | $270.0K | — | — | — | — | — | — | — | $76.6K | $87.1K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020419.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $23.2K | $42.5K | $12.5M | $37.3M | $92.9M | $119.0M | $152.5M | $154.8M | $194.1M |
| Gross profit | $3.3M | $2.7M | $6.3M | $9.9M | $28.4M | $74.9M | $100.4M | $133.6M | $133.4M | $166.3M |
| Net income | -$1.1M | -$1.2M | -$1.2M | -$3.1M | -$58.6M | -$60.9M | -$45.5M | $17.8M | $24.5M | -$11.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8011
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc. | $6.42B | 54.3x | 59.0% |
| TDOC | Teladoc Health, Inc. | $1.15B | — | -1.5% |
| STLN | Starling Oncology, Inc. | $683.9M | — | 27.8% |
| SBC | SBC Medical Group Holdings Inc | $543.0M | 10.6x | -15.5% |
| AIRS | Airsculpt Technologies, Inc. | $86.5M | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | — | — | 26.6% |
| BMGL | Basel Medical Group Ltd | — | — | — |